News
Dynavax delivers record Q2 results with $92M in HEPLISAV-B revenue, updates 2025 guidance, and advances pipeline milestones.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback